You are here

Retinal eye-tracking for the prognosis and monitoring of multiple sclerosis

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41NS100222-01A1
Agency Tracking Number: R41NS100222
Amount: $225,392.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NINDS
Solicitation Number: PA16-303
Timeline
Solicitation Year: 2016
Award Year: 2018
Award Start Date (Proposal Award Date): 2018-03-01
Award End Date (Contract End Date): 2018-09-30
Small Business Information
1771 HIGHLAND PL STE 8
Berkeley, CA 94709-1065
United States
DUNS: 079570312
HUBZone Owned: No
Woman Owned: Yes
Socially and Economically Disadvantaged: No
Principal Investigator
 CHRISTY SHEEHY
 (518) 339-2895
 christy.sheehy@berkeley.edu
Business Contact
 ZACHARY HELFT
Phone: (518) 428-3354
Email: zhelft@gmail.com
Research Institution
 UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
 
3333 CALIFORNIA STREET., STE 315
SAN FRANCISCO, CA 94118-6215
United States

 Nonprofit college or university
Abstract

Abstract
The goal of this project is to validate an innovativehighly sensitive retinal eye tracking
technologythe tracking scanning laser ophthalmoscopeTSLOas a prognostic and monitoring
tool for neurodegenerative disordersnamely multiple sclerosisMSThe applications of effective
treatments for multiple sclerosis are constrained bythe absence of methods for early detection
andquantitativehighly sensitive methods monitoring deficits early in disease course when
treatment may have a better chance of successAs already demonstratedthe TSLO is capable
of rapidly assessing and measuring the extraordinarily finemicroscopic motion of the human eye
during fixation in MS patientsFixational eye movements are neurally encodedinvoluntary
movements that require the coordination of many areas of the central nervous systemGiven the
TSLO s theoretical sensitivity to changearcminutesand its precision of measurementfixational eye movements have the potential utility for tracking neurodegenerative disease
progression at an unprecedented scaleWith the advent of the new FDA approved MS treatment
targeting B cellsocrelizumabclinical tools are now desperately needed to not only assess
treatment efficacybut to objectively assess patient disability at the earliest stage of disease in
order to cut relapse rates and prevent irrevocable disabilityIn this projectwe will determine the
optimal fixational eye motion metrics to distinguish patients from controlsestablish the
relationship between clinical disease severity measures and fixational eye movement deficits as
defined by the TSLO systemand to use machine learning algorithms to further strengthen our
fixational metrics Narrative
The goal of our project is to clinically validate a retinal imaging and eye tracking technologythe
tracking scanning laser ophthalmoscopeTSLOas a prognostic and monitoring tool for
neurodegenerative disordersparticularly Multiple SclerosisMSThe TSLO system is capable
of rapidly assessing and measuring the extraordinarily finemicroscopic motion of the human eye
during fixation with an accuracy ofarcminutesGiven the numerous brain regions involved
with eye motion and the TSLO s precision of measurementfixational eye movements now have
the potential utility for tracking neurodegenerative disease progression for the MS patient
population

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government